We identify the risk of developing Maternal Autoantibody Related Autism (MARA), a subtype of autism that is estimated to represent approximately 20% of overall cases, through a new type of risk assessment test for prospective mothers prior to (but not during) pregnancy, and for mothers during the early postnatal period. Our goal is to provide families with options to materially reduce the occurrence or severity of MARA. Our precision technology uses a blood test in women to identify the presence of a distinct cluster of autoantibodies that lead to MARA, thereby enabling the earliest risk assessment for the development of autism in a child.
Company Details
- Employees
- 14
- Founded
- 2016
- Address
- 26 S Rio Grande St,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://marabio.com/
- Keywords
- https://lnkd.in/gv7hcFXb.
- HQ
- Salt Lake City, Utah
Marabio Questions
Marabio's website is https://marabio.com/
Marabio's LinkedIn profile is https://www.linkedin.com/company/marabio-inc
Marabio has
14 employees.
View email and phone details for 14
employees at Marabio.
Marabio's industry is
Biotechnology Research
Marabio's top competitors are
Petra Capital Partners,
Headspace,
Reachout Australia,
Eleanor Health,
Biorosa Technologies,
Options Md,
Resilience Lab,
Aif,
Inherent Biosciences, Inc.,
Seek Labs.
Marabio's categories are Biotechnology Research
Marabio's founding year is 2016
